Shell Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Shell Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,956	Closed	-$29K	–	1425
2022 Q1	$29K	Sell	5,956 -931	-14%	-$5.16K	﹤0.01%	1365
2021 Q4	$48K	Sell	6,887 -96	-1%	-$746	﹤0.01%	1372
2021 Q3	$70K	Sell	6,983 -280	-4%	-$3.15K	﹤0.01%	1340
2021 Q2	$103K	Hold	7,263	–	–	﹤0.01%	1357
2021 Q1	$119K	Buy	+7,263	New	+$140K	﹤0.01%	1255

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Shell Asset Management's OCUL Position: Q2 2022 in Review

Shell Asset Management sold out of Ocular Therapeutix (OCUL) in Q2 2022, closing a stake of 5,956 shares — an estimated $29K sold.

Shell Asset Management first reported a position in OCUL in Q1 2021 and held it in 5 quarters. The position peaked at $119K in Q1 2021. 123 funds tracked by Wall St. Rank hold OCUL as of Q2 2022.

Shell Asset Management reported no remaining Ocular Therapeutix position as of Q2 2022 after selling out during the quarter.
Shell Asset Management sold 5,956 Ocular Therapeutix shares in Q2 2022, an estimated $29K.
Shell Asset Management first reported a position in Ocular Therapeutix in Q1 2021 and held it in 5 quarters.
Shell Asset Management's Ocular Therapeutix position peaked at $119K in Q1 2021.
123 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2022.

Based on Shell Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.